MarketBeat
17 Nov 2026, 07:12 UTC · 5h ago
Insmed Sees BRINSUPRI Reaching $7 Billion in Peak Sales, Expects Cash-Flow Positive Year Ahead
Impact · against what's priced in
Insmed is positioned for a significant valuation re-rating driven by a rapid BRINSUPRI launch and a path to cash-flow positivity by 2027. The $7 billion peak sales target and the imminent ARIKAYCE frontline regulatory decision provide substantial upside catalysts beyond current revenue baselines.
- INSM+0.80
No priced-in read yet





